Efficacy and safety of daratumumab-based combined regimens for treatment of multiple myeloma
10.3760/cma.j.cn115356-20220303-00063
- VernacularTitle:以达雷妥尤单抗为基础的联合方案治疗多发性骨髓瘤的效果及安全性
- Author:
Xinying MA
1
;
Qian HUANG
;
Chunyan YANG
;
Yu HUANG
;
Lu JIA
;
Lei LIU
;
Jingjing ZHANG
;
Saisai REN
;
Hao ZHANG
Author Information
1. 济宁医学院临床医学院，济宁 272000
- Keywords:
Multiple myeloma;
Daratumumab;
Drug therapy, combination;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2022;31(9):544-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and efficacy of daratumumab in the treatment of multiple myeloma (MM).Methods:The clinical data of 19 MM patients treated with daratumumab alone or in combination with chemotherapy regimens from June 2021 to December 2021 in the Affiliated Hospital of Jining Medical College were retrospectively analyzed, of which 2 patients received daratumumab alone, 6 cases received daratumumab combined with lenalidomide+dexamethasone (DRD) regimen, 1 case received daratumumab combined with liposomal doxorubicin+dexamethasone (DVD) regimen, 2 case received daratumumab combined with dexamethasone+cyclophosphamide+etoposide+cisplatin (DECP) regimen, 3 cases received daratumumab combined with isazomib+dexamethasone (ID) regimen, 2 cases received daratumumab combined with bortezomib+dexamethasone (BD) regimen, and 3 cases received daratumumab combined with dexamethasone (DD) regimen. The efficacy and incidence of adverse effects were analyzed.Results:Among the 19 patients, 8 had complete remission (CR), 1 had very good partial remission (VGPR), 5 had partial remission (PR), 1 had stable disease (SD), and 4 had progressive disease (PD). The overall response rate (ORR) was 73.7% (14/19). The median progression-free survival (PFS) time was 10.42 months (95% CI 8.04-12.79 months) and the median overall survival (OS) time was 52.06 months (95% CI 37.85-66.27 months). The main adverse reactions during treatment were grade 3 neutropenia in 3 cases, grade 3 lymphopenia in 3 cases, grade 2 anemia in 5 cases, grade 2 nausea and vomiting in 7 cases, and infusion-related adverse reactions in 7 cases. Conclusions:Daratumumab-based chemotherapy regimens for the treatment of MM patients can achieve great efficacy with good safety and tolerability.
